Evelo Biosciences
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
Evelo Biosciences, along with Rutgers University and Robert Wood Johnson University Hospital, is driving toward a Phase II study of an investigational treatment for hospitalized patients with newly diagnosed COVID-19.
Evelo Biosciences, Inc., a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures, a healthcare investment firm.
JOBS
IN THE PRESS